Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments (Q37947081)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 October 2011

Language	Label	Description	Also known as
English	Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments	scientific article published on 18 October 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

1 reference

15 October 2020

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments (English)

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

Adaptive radiation therapy

0 references

hormone-dependent neoplasms

1 reference

3 April 2019

1 reference

17 November 2019

hormonal antineoplastic agent

1 reference

15 October 2020

prostate neoplasm

1 reference

15 October 2020

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

H Payne

1

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

M Mason

2

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

language of work or name

0 references

publication date

18 October 2011

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

22 November 2011

3 references

3 April 2019

17 November 2019

15 October 2020

British Journal of Cancer

4 references

Europe PubMed Central

PMC publication ID

25 August 2017

3 April 2019

17 November 2019

15 October 2020

105

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

1628-1634

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2011.385

0 references

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

6 September 2017

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

23 June 2018

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

23 June 2018

Duration of androgen suppression in the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Is Bicalutamide Equivalent to Goserelin for Prostate Volume Reduction before Radiation Therapy? A Prospective, Observational Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242586

1 September 2018

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://pubmed.ncbi.nlm.nih.gov/22009028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.385

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BJC.2011.385

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

25 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37947081&oldid=2163306466"